Biomerica, Inc.
corporate_fare Company Profile
Biomerica, Inc. (NASDAQ:BMRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for BMRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-16, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for BMRA spans 10-Q, 10-K/A, 10-K, 8-K.
Recent high-impact activity:
- Biomerica Posts $1.20 Per-Share Q1 Loss as Cash Crunch Deepens
- Biomerica Q1 Loss Widens to $1.2M; Going-Concern Doubt Reiterated Despite $2.7M Cash
- Biomerica 10-K/A Reveals CEO's $500K Related-Party Note and New Finance Chief
- Biomerica 10-K: Going Concern Warning, 300M Authorized Shares, Nasdaq Delisting Risk
- Biomerica Secures $2.23M via Private Placement at $1.60/Share, Grants B. Riley Board Seat
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 10,485 shares in BMRA as of the October 15, 2026 settlement, a 62.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 26, 2026, 48.0% of BMRA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BMRA, detected from its recent SEC filings · based on capital-structure filings through 2026-09-25.
$250M Universal Shelf Registered · No Immediate Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →